Gastroesophageal Reflux Disease Therapeutics Market Size Report, 2023-2032
The global gastroesophageal reflux disease therapeutics market size was exhibited at USD 6.19 billion in 2022 and is projected to hit around USD 7.38 billion by 2032, growing at a CAGR of 1.77% during the forecast period 2023 to 2032.
Key Pointers:
Gastroesophageal Reflux Disease Therapeutics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 6.3 Billion |
| Market Size by 2032 | USD 7.38 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 1.77% |
| Base year | 2022 |
| Forecast period | 2023 to 2032 |
| Segments covered | Drug type |
| Regional scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key companies profiled |
AstraZeneca; Eisai Co. Ltd.; GSK plc.; Takeda Pharmaceutical Company Limited.; Ironwood Pharmaceuticals, Inc.; Johnson & Johnson Services; Inc.; SFJ Pharmaceuticals; Sebela Pharmaceuticals; Phathom Pharmaceuticals Inc.; Camber Pharmaceuticals Inc. |
The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.
Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.
Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.
Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.
North America dominated the overall gastroesophageal reflux disease treatment market in 2022, which can be attributed to the increasing adoption of GERD therapeutics owing to the increasing prevalence of GERD in the regional population. For instance, according to a study published in the journal GUT, the prevalence of GERD in North America was 18-28%. Moreover, there are increasing initiatives on spreading awareness about the condition in the population, further increasing the demand for GERD therapeutics. For instance, in November 2022, EndoGastric Solutions, Inc. launched a national campaign for supporting GERD awareness week. The aim of the campaign was to provide easy-to-follow reflux-friendly recipes for people suffering from GERD. The growth in the region is also supported by key players focusing on new product launches. In October 2022, Sebela Pharmaceuticals entered into a strategic collaboration for the development and commercialization of Tegoprazan in Canada and the U.S.
Asia Pacific is estimated to show the fastest growth over the forecast period. The growth of the market in the region is due to increasing awareness among the target audience regarding the treatment of the condition, increasing incidences, and an increasing focus by key market players to expand their product portfolios. In March 2022, Vonoprazan, an FDA-approved drug developed by Phantom Pharmaceuticals, was made commercially available in Japan and other Asian countries for the treatment of GERD. Moreover, a number of players have expanded their presence in Asia owing to increasing demand for GERD therapeutics in the region.
Some of the prominent players in the Gastroesophageal Reflux Disease Therapeutics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Gastroesophageal Reflux Disease Therapeutics market.
By Drug Type
By Region
Chapter 1 Gastroesophageal Reflux Disease Therapeutics Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 List Of Secondary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.11 List Of Abbreviations
Chapter 2 Gastroesophageal Reflux Disease Therapeutics Market: Executive Summary
2.1 Gastroesophageal Reflux Disease Therapeutics Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Gastroesophageal Reflux Disease Therapeutics Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Low Success Rates Of Gerd Management Devices, Leading To Higher Adoption Of Therapeutics
3.3.1.2 Rising Prevalence Of Gerd And Other Gastrointestinal Disorders
3.3.1.3 Rising Trend For Self Medication And Presence Of Strong Product Pipeline
3.3.2 Market Restraint Analysis
3.3.2.1 Patent expiry of blockbuster drugs prescribed
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Gastroesophageal Reflux Disease Therapeutics Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2023
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis
5.1 Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Movement Analysis
5.2 Antacids
5.2.1 Antacids Market Estimates And Forecast, 2020 - 2032
5.3 H2 Receptor Blockers
5.3.1 H2 Receptor Blockers Market Estimates And Forecast, 2020 - 2032
5.4 Proton Pump Inhibitors (Ppis)
5.4.1 Proton Pump Inhibitors (Ppis) Market Estimates And Forecast, 2020 - 2032
5.5 Pro-Kinetic Agents
5.5.1 Pro-Kinetic Agents Market Estimates And Forecast, 2020 - 2032
Chapter 6 Gastroesophageal Reflux Disease Therapeutics Market: Regional Business Analysis
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2032
6.3 Regional Market Dashboard
6.4 Regional Market Snapshot
6.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
6.5.1 North America
6.5.2 Europe
6.5.3 Asia Pacific
6.5.4 Latin America
6.5.5 MEA
6.6 Market Size, & Forecasts, Trend Analysis, 2021 To 2032
6.7 North America
6.7.1 North America Market Estimates And Forecast, 2020 - 2032
6.7.2 U.S.
6.7.2.1 U.S. Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.7.2.2 Key Country Dynamics
6.7.2.3 Regulatory Framework
6.7.2.4 Competitive Scenario
6.7.2.5 Recent Developments
6.7.2.6 Investments Scenario
6.7.3 Canada
6.7.3.1 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.7.3.2 Key country Dynamics
6.7.3.3 Regulatory Framework
6.7.3.4 Competitive Scenario
6.7.3.5 Recent Developments
6.7.3.6 Investments Scenario
6.8 Europe
6.8.1 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.2 UK
6.8.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.2.2 Key country Dynamics
6.8.2.3 Regulatory Framework
6.8.2.4 Competitive Scenario
6.8.2.5 Recent Developments
6.8.2.6 Investments Scenario
6.8.3 Germany
6.8.3.1 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.3.2 Key Country Dynamics
6.8.3.3 Regulatory Framework
6.8.3.4 Competitive Scenario
6.8.3.5 Recent Developments
6.8.3.6 Investments Scenario
6.8.4 Spain
6.8.4.1 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.4.2 Key Country Dynamics
6.8.4.3 Regulatory Framework
6.8.4.4 Competitive Scenario
6.8.4.5 Recent Developments
6.8.4.6 Investments Scenario
6.8.5 France
6.8.5.1 France Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.5.2 Key Country Dynamics
6.8.5.3 Regulatory Framework
6.8.5.4 Competitive Scenario
6.8.5.5 Recent Developments
6.8.5.6 Investments Scenario
6.8.6 Italy
6.8.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.6.2 Key Country Dynamics
6.8.6.3 Regulatory Framework
6.8.6.4 Competitive Scenario
6.8.6.5 Recent Developments
6.8.6.6 Investments Scenario
6.8.7 Denmark
6.8.7.1 Denmark Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.7.2 Key Country Dynamics
6.8.7.3 Regulatory Framework
6.8.7.4 Competitive Scenario
6.8.7.5 Recent Developments
6.8.7.6 Investments Scenario
6.8.8 Sweden
6.8.8.1 Sweden Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.8.2 Key Country Dynamics
6.8.8.3 Regulatory Framework
6.8.8.4 Competitive Scenario
6.8.8.5 Recent Developments
6.8.8.6 Investments Scenario
6.8.9 Norway
6.8.9.1 Norway Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.8.9.2 Key Country Dynamics
6.8.9.3 Regulatory Framework
6.8.9.4 Competitive Scenario
6.8.9.5 Recent Developments
6.8.9.6 Investments Scenario
6.9 Asia Pacific
6.9.1 Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.2 Japan
6.9.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.2.2 Key Country Dynamics
6.9.2.3 Regulatory Framework
6.9.2.4 Competitive Scenario
6.9.2.5 Recent Developments
6.9.2.6 Investments Scenario
6.9.3 China
6.9.3.1 China Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.3.2 Key Country Dynamics
6.9.3.3 Regulatory Framework
6.9.3.4 Competitive Scenario
6.9.3.5 Recent Developments
6.9.3.6 Investments Scenario
6.9.4 India
6.9.4.1 India Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.4.2 Key Country Dynamics
6.9.4.3 Regulatory Framework
6.9.4.4 Competitive Scenario
6.9.4.5 Recent Developments
6.9.4.6 Investments Scenario
6.9.5 South Korea
6.9.5.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.5.2 Key Country Dynamics
6.9.5.3 Regulatory Framework
6.9.5.4 Competitive Scenario
6.9.5.5 Recent Developments
6.9.5.6 Investments Scenario
6.9.6 Thailand
6.9.6.1 Thailand Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.6.2 Key Country Dynamics
6.9.6.3 Regulatory Framework
6.9.6.4 Competitive Scenario
6.9.6.5 Recent Developments
6.9.6.6 Investments Scenario
6.9.7 Australia
6.9.7.1 Australia Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.9.7.2 Key Country Dynamics
6.9.7.3 Regulatory Framework
6.9.7.4 Competitive Scenario
6.9.7.5 Recent Developments
6.9.7.6 Investments Scenario
6.10 Latin America
6.10.1 Latin America Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.10.2 Brazil
6.10.2.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.10.2.2 Key Country Dynamics
6.10.2.3 Regulatory Framework
6.10.2.4 Competitive Scenario
6.10.2.5 Recent Developments
6.10.2.6 Investments Scenario
6.10.3 Mexico
6.10.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.10.3.2 Key Country Dynamics
6.10.3.3 Regulatory Framework
6.10.3.4 Competitive Scenario
6.10.3.5 Recent Developments
6.10.3.6 Investments Scenario
6.10.4 Argentina
6.10.4.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.10.4.2 Key Country Dynamics
6.10.4.3 Regulatory Framework
6.10.4.4 Competitive Scenario
6.10.4.5 Recent Developments
6.10.4.6 Investments Scenario
6.11 MEA
6.11.1 MEA Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.11.2 South Africa
6.11.2.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.11.2.2 Key Country Dynamics
6.11.2.3 Regulatory Framework
6.11.2.4 Competitive Scenario
6.11.2.5 Recent Developments
6.11.2.6 Investments Scenario
6.11.3 Saudi Arabia
6.11.3.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.11.3.2 Key Country Dynamics
6.11.3.3 Regulatory Framework
6.11.3.4 Competitive Scenario
6.11.3.5 Recent Developments
6.11.3.6 Investments Scenario
6.11.4 Uae
6.11.4.1 Uae Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.11.4.2 Key Country Dynamics
6.11.4.3 Regulatory Framework
6.11.4.4 Competitive Scenario
6.11.4.5 Recent Developments
6.11.4.6 Investments Scenario
6.11.5 Kuwait
6.11.5.1 Kuwait Gastroesophageal Reflux Disease Therapeutics Market, 2020 - 2032
6.11.5.2 Key Country Dynamics
6.11.5.3 Regulatory Framework
6.11.5.4 Competitive Scenario
6.11.5.5 Recent Developments
6.11.5.6 Investments Scenario
Chapter 7 Gastroesophageal Reflux Disease Therapeutics Market: Company Profiling
7.1 Company Profiles
7.1.1 Astrazeneca
7.1.1.1 Company Overview
7.1.1.2 Financial Performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic Initiatives
7.1.2 Eisai Co., Ltd.
7.1.2.1 Company Overview
7.1.2.2 Financial Performance
7.1.2.3 Product Benchmarking
7.1.2.4 Strategic Initiatives
7.1.3 Gsk Plc.
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 Takeda Pharmaceutical Company Limited.
7.1.4.1 Company Overview
7.1.4.2 Financial Performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 Ironwood Pharmaceuticals, Inc.
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic Initiatives
7.1.6 Johnson & Johnson Services, Inc.
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic Initiatives
7.1.7 Sfj Pharmaceuticals
7.1.7.1 Company Overview
7.1.7.2 Financial Performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 Sebela Pharmaceuticals
7.1.8.1 Company Overview
7.1.8.2 Financial Performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 Phathom Pharmaceuticals, Inc.
7.1.9.1 Company Overview
7.1.9.2 Financial Performance
7.1.9.3 Product Benchmarking
7.1.9.4 Strategic Initiatives
7.1.10 Camber Pharmaceuticals, Inc.
7.1.10.1 Company Overview
7.1.10.2 Financial Performance
7.1.10.3 Product Benchmarking
7.1.10.4 Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers